What does the evidence say about Vitamin D Hair Loss Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Vitamin D Hair Loss Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Background/objectives Sensorineural hearing loss (SNHL) is a chronic condition with no established pharmacological treatment. [Mavandi M (2026); evidence level 3] - Recent advances in drug-based therapies offer promising opportunities to prevent or treat SNHL. [Mavandi M (2026); evidence level 3] - Multiple observational studies have demonstrated that serum 25-hydroxyvitamin D levels are significantly lower in SSNHL patients than in healthy controls, with deficiency associated with greater hearing impairment, poorer treatment response, and higher recurrence risk. [Wang Y (2026); evidence level 3] - However, it must be emphasized that no standardized serum threshold, population-specific validation, or universally accepted predictive model currently exists; therefore, serum 25(OH)D should be regarded as a candidate-rather than an established-biomarker for SSNHL risk stratification. [Wang Y (2026); evidence level 3] - Sudden sensorineural hearing loss (SSNHL) is defined as a rapid hearing decline of ≥30 dB across at least three contiguous frequencies within 72 h, with a multifactorial etiology encompassing vascular, viral, autoimmune, and metabolic mechanisms. [Wang Y (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.